They've built a fabulous brand, but this is a cult stock which doesn't support the stock fundamentals. Is it worth 95x enteprise value when GM is at 6x. There's danger in this high-beta stock. The stock price fluctuates a lot based on emotion.
Ford vs. GM This and GM are heavily moving towards e-cars. GM is bigger than Ford and more cost-efficient with far better operating margins. Long-term, GM will offer better products. Ford has been relying on the F-150, while GM has just surpassed them in total truck sales. He likes that GM is the majority owner of the Cruise self-driving business, partnering with Microsoft (https://www.reuters.com/article/us-gm-microsoft-autonomous-idUSKBN29O1MO). Ford isn't a bad option, but GM is the best.
This and GM are heavily moving towards e-cars. GM is bigger than Ford and more cost-efficient with far better operating margins. Long-term, GM will offer better products. Ford has been relying on the F-150, while GM has just surpassed them in total truck sales. He likes that GM is the majority owner of the Cruise self-driving business, partnering with Microsoft (https://www.reuters.com/article/us-gm-microsoft-autonomous-idUSKBN29O1MO). Ford isn't a bad option, but GM is the best.
An infrastructure company in telecoms; their biggest customers are telecoms like Verizon and Comcast. They string the contintent for 5G capability. Warning: It's a lumpy business, because it's bsed on fixed costs. However, Dycom is getting a lot of positive attention because they are the go-to business to lay the fibre optics for the coming 5G revolution. This can easily earn $6/share, so it's not expensive now. (Analysts’ price target is $102.00)
(A Top Pick May 12/20, Up 24%) He's sticking with it. There's more upside to come. Their biggest product was Humera, a massive drug. A few years ago, they bought Allergan and their Botox drug, which reduced company dependence on Humera for company revenues. ABBV has some new drugs in the pipeline that are reaching $1 billion in sales, so this further spreads the risk away from Humera. It trades at a cheap 9x PE and pays a 5% dividend. Warning: in 2023, Humera goes off patent and that will mean a challenge for ABBV to replace that revenue stream (Humera makes up 32% of all revenues, though it used to be 65% before Botox).